During the recent session, Astrazeneca plc ADR (NASDAQ:AZN)’s traded shares were 1.44 million, with the beta value of the company hitting 0.49. At the last check today, the stock’s price was $74.79, reflecting an intraday loss of -0.33% or -$0.24. The 52-week high for the AZN share is $75.81, that puts it down -1.36 from that peak though still a striking 19.15% gain since the share price plummeted to a 52-week low of $60.47. The company’s market capitalization is $231.87B, and the average trade volume was 6.36 million shares over the past three months.
Astrazeneca plc ADR (NASDAQ:AZN) trade information
Astrazeneca plc ADR (AZN) registered a -0.33% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.33% in intraday trading to $74.79, hitting a weekly high. The stock’s 5-day price performance is 9.10%, and it has moved by 9.56% in 30 days. Based on these gigs, the overall price performance for the year is 1.54%.
Astrazeneca plc ADR (AZN) estimates and forecasts
Statistics show that Astrazeneca plc ADR has outperformed its competitors in share price, compared to the industry in which it operates. Astrazeneca plc ADR (AZN) shares have gone up 16.47% during the last six months, with a year-to-date growth rate more than the industry average at 10.47% against 3.90. In the rating firms’ projections, revenue will increase 11.50% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 12.52B as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 12.87B by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 10.96B and 11.55B respectively. In this case, analysts expect current quarter sales to grow by 14.20% and then jump by 11.40% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 17.72%. While earnings are projected to return 12.23% in 2024, the next five years will return 13.20% per annum.
AZN Dividends
Astrazeneca plc ADR is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance. Investors should also take the other fundamental and operational aspects into account before investing in the stock. The forward dividend ratio for Astrazeneca plc ADR is 1.45, with the dividend yield indicating at 1.94 percent, continuing the trend of increasing dividends in recent years.
